Merck (MRK) Stock May Be 35% Undervalued After Cancer Vaccine Data

Merck stock has delivered a strong 130.2% return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market multiples lean the other way.

• Over 5 years, Merck has returned 130.2%, which puts recent enthusiasm for the story firmly in focus for anyone thinking about new money going into the stock.
• Recent progress in oncology, including the personalized mRNA melanoma vaccine with Moderna and broader use of Keytruda, can support higher long term cash flow expectations, while concerns about future loss of exclusivity on some products may limit how much investors are willing to pay today.
• Merck scores just 2 out of 6 on broader valuation checks, which suggests the stock is not a clear bargain even though the intrinsic value estimate indicates it may be about 35.3% undervalued.

The issue now is whether Merck’s recent gains already reflect its cancer pipeline and partnerships, or whether the DCF based intrinsic value points to further room for upside from here.

Merck delivered 82.5% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is Merck a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here values Merck on the cash it is expected to generate for shareholders over time. Merck currently produces last twelve month free cash flow of about $16.1b, and the model assumes these cash flows keep growing rather than shrinking, which supports an estimated intrinsic value of about $233 per share.

Against the current share price, that DCF output implies Merck appears around 35.3% undervalued on a cash flow basis. The Phase 3 success of the personalized mRNA melanoma vaccine with Moderna helps explain why analysts consider a growing long term cash flow profile while the market still prices in concerns about future patent expiries.

On this DCF view, Merck appears undervalued relative to what its projected cash flows would justify.

Our Discounted Cash Flow (DCF) analysis suggests Merck is undervalued by 35.3%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Merck.

Does Merck Look Pricey on Earnings?

The P/E ratio fits Merck well because earnings remain a key yardstick for large, established pharmaceutical companies. On this measure, Merck trades on a P/E of about 117.1x, which is far above the Pharmaceuticals industry average of 16.8x and the peer group average of 31.1x. That already indicates the market is assigning a very rich price to each dollar of current earnings.

The tailored fair P/E ratio for Merck is estimated at 46.7x, which already reflects its specific growth profile, margins, scale and risks. The gap between that figure and the current 117.1x indicates the stock is pricing in a lot of optimism relative to what this framework would usually support for a company like Merck. The strong excitement around the oncology pipeline and mRNA cancer vaccine partnerships is reflected in this premium, even though those drivers are already part of the broader discussion on the stock.

On the P/E multiple, Merck stock currently screens as overvalued relative to both its tailored fair ratio and typical industry levels.

See what the numbers say about this price — find out in our valuation breakdown.

The Merck Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives help connect Merck’s split valuation picture to specific future paths for growth, margins and earnings. Each narrative sets out what would need to happen in Merck’s business for the stock to be worth materially more or less than today’s price, and it ties those views to a clear set of assumptions about growth, profitability and risks that you can revisit as new information comes through. These are available on Simply Wall St’s Community page and give you a structured way to think about what the market might be pricing in.

Community views on Merck sit far apart, with one camp focused on a long runway for late stage assets and another worried about execution and the patent cliff.

Bull case: roughly fairly valued

“Breakthroughs in biotechnology and biomarker-driven precision medicine are accelerating Merck’s R&D productivity, with a record number of registrational trials and novel mechanisms under development…”

Read the full Bull Case to see why Merck could be undervalued

Bear case: 10% overvalued

“The eventual loss of exclusivity (LOE) for KEYTRUDA could lead to significant revenue decline if the pipeline doesn’t compensate for this gap…”

Read the full Bear Case to see why Merck could be overvalued

Do you think there’s more to the story for Merck? Head over to our Community to see what others are saying!

The Bottom Line

For Merck, the Discounted Cash Flow (DCF) intrinsic value suggests the stock trades at a meaningful discount, while the P/E based view points to an overvalued multiple that already bakes in strong expectations. The split largely comes down to timing and confidence in future cash flows versus what investors are currently willing to pay for each dollar of earnings. Broader valuation checks are weak, so that DCF signal deserves extra scrutiny rather than blind faith. The key question from here is whether Merck’s pipeline and oncology partnerships can offset patent expiry risks enough to justify both the premium earnings multiple and the implied intrinsic value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com